Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIMUS-EL: Letermovir for CMV Prophylaxis in RRMM Patients on Elranatamab
NCT06920251Phase 2Recruiting
- Sponsor
- Seoul National University Hospital
- Start
- Sep 2025
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of letermovir in cytomegalovirus infection (CMV), sponsored by Seoul National University Hospital. Started Sep 2025; status: recruiting.
02
Drugs
letermovir
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT06920251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06920251.